Homology Medicines have received clearance from Health Canada to initiate the juMPStart trial for HMI-203, a one-time, in vivo gene therapy candidate for the treatment of adults with Hunter Syndrome (MPS II). If you are interested in knowing more, join Homology...
The 2022 Canadian MPS Society Annual General Meeting will be held on: Monday 26 September 2022 7:30 pm – 8:30 pm EST (4:30 pm – 5:30 pm PST). The meeting will be held online. Access details will be sent out in a separate email to...
The MPS group is a rare but extraordinary one with Community at our heart. Join our incredible team of Directors in 2022 to help oversee the organisation’s strategic purpose and direction. Your leadership can have a life changing impact on the...
Receiving a diagnosis is difficult for those who love us. In this podcast by Beyond My Battle, two caregivers provide their perspectives on what it felt like. Steve is the parent of a child with Sanfilippo syndrome and Sarah is the parent of a child with Down...
New data from the AAVance trial has revealed children with Sanfilippo syndrome type A, including those with severe disease, showed stable or continuously increasing cognitive, language, and motor functions two years after dosing with the investigational gene therapy...
Avrobio has received orphan drug designation for its gene therapy, AVR-RD-05, from the US Food and Drug Administration (FDA) to treat mucopolysaccharidosis type II or Hunter syndrome. and is expected to initiate a Phase I/II clinical trial for MPS II in partnership...
